| This week's sponsor is Premier Research. | | | Clearing the Path for Orphan Drug Development
The unmet therapeutic need in rare disease is huge, but so are the cost and complexity of drug development. Read our white paper to see how the FDA and EMA are easing the path to regulatory approval. Premier Research. It's what we do. Best. |
Top Stories Wednesday, December 7, 2016 Chinese researchers are publishing more than three times as many research papers on cancer topics than they were a decade ago, closing the gap with their U.S. counterparts. Wednesday, December 7, 2016 Neurimmune and TVM Capital Life Science have partnered to create and fund a single-asset biotech focused on amyotrophic lateral sclerosis. The biotech, AL-S Pharma, plans to work with Eli Lilly unit Chorus to take a human monoclonal antibody targeting misfolded SOD1 to proof of concept. Wednesday, December 7, 2016 MicroRNA specialist Regulus has bulked up its pipeline with two new clinical candidates for liver and kidney diseases that could start human trials next year. Wednesday, December 7, 2016 Nordic Nanovector has raised $60 million in an oversubscribed private placement. The cash injection will enable Nanovector to test its CD37-targeting antibody-radionuclide conjugate (ARC) in combination with rituximab, better known as Roche’s cancer powerhouse Rituxan. Tuesday, December 6, 2016 French digital health player Voluntis announced twin approvals on Tuesday, snagging a CE mark and FDA clearance for its management device for Type 2 diabetics who are treated with basal insulin. Monday, December 5, 2016 Charles River Laboratories has launched CRISPR/Cas9 services through a licensing deal with the Broad Institute, as a dispute over ownership of the gene-editing technology gathers pace. Wednesday, December 7, 2016 The U.K. government slapped Pfizer with a record price-gouging fine for triggering a 2,600% price increase on an epilepsy drug by "deliberately exploiting" a loophole in the country's price-control rules. Pfizer "refutes the findings" and says it will appeal. | | | On the back of some strong early data out of ASH this week, Bluebird Bio has started a $250 million public offering of its common stock. Release Boehringer says it has found "clinically meaningful" data for its oral med nintedanib, which is already on the market for several conditions, in the aggressive, asbestos-related lung cancer mesothelioma. Statement Novartis' former head of the Swiss pharma's now-dwindling cell and gene therapies Usman “Oz” Azam has become the new CEO at Tmunity Therapeutics. Release | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. 24th International Molecular Medicine Tri-Conference February 19-24, 2017 | Moscone North Convention Center | San Francisco, CA CBI’s IISR 2017 Summit February 14-15, 2017 | Philadelphia, PA FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA Precision LBx Summit: Translating Next Generation Liquid Biopsies into Clinical Reality January 30-February 1, 2017 | San Diego, CA DeviceTalks December 12, 2016 | Newport Beach, CA | 